With rapidly increasing functionality, affordability and ownership of mobile digital technologies, the field of mobile health (mHealth) has proliferated in recent years. There is a growing recognition of mHealth's tremendous potential to enrich care and management of a range of physical and mental health problems across the globe. A successful implementation of effective mHealth initiatives would also eliminate barriers such as financial hardships and poor access to care, for example, in remote areas that may be hard to reach.
A number of studies, including SIMPle (Hidalgo-Mazzei et al., 2015) and CLIMB (Biagianti et al., 2016) , have already established that the remote, active or passive, highfrequency and real-time data from mobile digital technologies, such as smartphones, offer unparalleled opportunities to address specific clinical challenges, identify unmet needs and deliver interventions in mental health disorders such as schizophrenia and bipolar disorder (BD). FaurholtJepsen et al. (2019) add yet another domain to mHealth by raising the possibility that mobile digital technologies capable of providing 'unbiased estimates of behavioural activities' may provide a diagnostic marker of BD.
Faurholt-Jepsen and colleagues examined whether automatically generated objective smartphone data collected over a 12-week period from adults with a clinical diagnosis of BD (n = 29) differentiated them from healthy adults (n = 37). They found an increase in the use of smartphone and communicative activities (the number of text messages sent and received per day, the duration of phone calls) during the euthymic, depressive, manic or mixed states (and overall) and a decrease in the amount of time the screen was 'on' per day during the euthymic and depressive states (and overall) in the BD group relative to the healthy control group.
So what do the findings of FaurholtJepsen et al.'s study actually mean for clinical psychiatry and mHealth initiatives? Can we really use smartphone data to diagnose BD? The findings certainly offer a novel method for quantifying behavioural and communication patterns in relation to specific mood states in BD and appear promising in showing a difference in automatically generated smartphone data between the BD and healthy groups, with a high sensitivity (i.e. the probability of BD being identified in those with a BD diagnosis = .92). Specificity, however, was rather low (.39), and this should be considered a significant issue for any potential diagnostic marker. Furthermore, as discussed by Faurholt-Jepsen and colleagues themselves, the observed increase in some of the phone use parameters was possibly triggered by a change in the behaviours of others, and did not index a true BD-linked change in patients' behavioural activities. For example, a higher number of texts received or sent per day by BD patients, relative to healthy controls, may simply reflect the concerns of their relatives or carers. If so, this may or may not be seen for those with a probable BD diagnosis but still to be formally diagnosed.
It is obvious that further data from ongoing (Kessing et al., 2017) and future longitudinal studies, especially those that include at-risk groups, are required to robustly assess the utility of objective smartphone data as a potential diagnostic marker of BD before the smartphone parameters investigated by Faurholt-Jepsen et al. could potentially replace, or even meaningfully aid, the current interview-based diagnosis of BD. It is hoped that other phone data such as the voice characteristics or speech patterns would add, especially to negative predictive value, and increase specificity of smartphone data as a diagnostic marker of BD. It is further hoped that by then the field in general would also be better equipped (e.g. with patient facing apps, capacity to achieve scalability and implementation and to deal effectively with confidentiality and trust issues) to realise full potential of mHealth and technology supported-self-management and care in psychiatry (Biagianti et al., 2017) .
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What are the goals of treatment of PD?
The specific goals of treatment of PD are not stated in Anxiety CPGs. Instead, one finds general goals of treatment of anxiety disorders, including recovery, reducing physical and cognitive symptoms and behavioural avoidance, as well as relapse prevention. Considering patients' goals and expectations of treatment is listed as a part of comprehensive assessment, but what these goals may involve is not elaborated.
Different therapeutic approaches to PD explicitly or implicitly espouse different goals. Some emphasise elimination and prevention of panic attacks, whereas others consider it more important to focus on the fear of further panic attacks and panic symptoms (i.e. anticipatory anxiety). Still other therapeutic modalities suggest that patients should be taught how to live with their panic attacks.
Clarity about treatment goals in PD is not an academic exercise. This is important to patients, and they should know from the very beginning of treatment what to expect and what not to expect. Furthermore, numerous studies have reported that PD is associated with an increased risk of cardiovascular morbidity and mortality, and the stipulation of treatment goals for PD then carries even more weight. For example, if the persistence of panic attacks is demonstrated to be a risk factor for cardiovascular diseases, prevention of panic attacks might become the main goal of treatment.
Selective serotonin reuptake inhibitors and PD
Along with other treatment guidelines, Anxiety CPGs endorse selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacotherapy for PD. This is controversial for several reasons.
First, SSRIs are not more efficacious for PD than agents such as benzodiazepines. In fact, the only study that directly compared an SSRI (paroxetine) with a benzodiazepine (clonazepam) over a long-term treatment of PD demonstrated that use of clonazepam predicted lower relapse rates (Freire et al., 2017) .
Second, SSRIs have numerous side effects, including gastrointestinal symptoms (nausea, diarrhoea, gastric bleeding, dyspepsia), agitation, dizziness, sexual dysfunction, hyponatremia, weight gain, increased suicidal ideation, sleep disturbances, cardiovascular abnormalities, osteoporosis and risk of fractures, sweating, bleeding tendencies, extrapyramidal symptoms and apathy (Carvalho et al., 2016) . There is evidence that side effects of benzodiazepines (e.g. sedation) are better tolerated than those of SSRIs during both short-term and long-term treatment of PD.
Third, SSRIs are associated with frequent and severe withdrawal See Research by 
